

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Enzalutamide

April 8, 2025

**Therapeutic category**

Other antitumor agents

**Non-proprietary name**

Enzalutamide

**Safety measure**

PRECAUTIONS should be revised.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)		
Patients receiving doravirine, ensitrelvir fumaric acid, <u>or</u> lenacapavir sodium			Patients receiving doravirine, ensitrelvir fumaric acid, lenacapavir sodium, <u>or nirmatrelvir/ritonavir</u>		
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Doravirine Ensitrelvir fumaric acid Lenacapavir sodium	The effects of these drugs may be attenuated by co-administration with enzalutamide.	The CYP3A4-inducing activity of enzalutamide may lead to a decrease in the blood concentration of these drugs.	Doravirine Ensitrelvir fumaric acid Lenacapavir sodium <u>Nirmatrelvir/ritonavir</u>	The effects of these drugs may be attenuated by co-administration with enzalutamide.	The CYP3A4-inducing activity of enzalutamide may lead to a decrease in the blood concentration of these drugs.